Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

117 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nuclear inclusion bodies of mutant and wild-type p53 in cancer: a hallmark of p53 inactivation and proteostasis remodelling by p53 aggregation.
De Smet F, Saiz Rubio M, Hompes D, Naus E, De Baets G, Langenberg T, Hipp MS, Houben B, Claes F, Charbonneau S, Delgado Blanco J, Plaisance S, Ramkissoon S, Ramkissoon L, Simons C, van den Brandt P, Weijenberg M, Van England M, Lambrechts S, Amant F, D'Hoore A, Ligon KL, Sagaert X, Schymkowitz J, Rousseau F. De Smet F, et al. Among authors: lambrechts s. J Pathol. 2017 May;242(1):24-38. doi: 10.1002/path.4872. Epub 2017 Mar 23. J Pathol. 2017. PMID: 28035683
Genetic changes in nonepithelial ovarian cancer.
Van Nieuwenhuysen E, Lambrechts S, Lambrechts D, Leunen K, Amant F, Vergote I. Van Nieuwenhuysen E, et al. Among authors: lambrechts s, lambrechts d. Expert Rev Anticancer Ther. 2013 Jul;13(7):871-82. doi: 10.1586/14737140.2013.811174. Expert Rev Anticancer Ther. 2013. PMID: 23875665 Review.
Epithelial ovarian cancer: rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment.
Despierre E, Yesilyurt BT, Lambrechts S, Johnson N, Verheijen R, van der Burg M, Casado A, Rustin G, Berns E, Leunen K, Amant F, Moerman P, Lambrechts D, Vergote I; EORTC GCG and EORTC GCG Translational Research Group. Despierre E, et al. Among authors: lambrechts s, lambrechts d. Int J Gynecol Cancer. 2014 Mar;24(3):468-77. doi: 10.1097/IGC.0000000000000089. Int J Gynecol Cancer. 2014. PMID: 24557434
Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer.
Lambrechts S, Lambrechts D, Despierre E, Van Nieuwenhuysen E, Smeets D, Debruyne PR, Renard V, Vroman P, Luyten D, Neven P, Amant F, Leunen K, Vergote I; Belgian and Luxembourg Gynaecological Oncology Group (BGOG). Lambrechts S, et al. Among authors: lambrechts d. BMC Pharmacol Toxicol. 2015 Feb 27;16:2. doi: 10.1186/s40360-015-0001-5. BMC Pharmacol Toxicol. 2015. PMID: 25881102 Free PMC article.
Ovarian cancer ascites induces skeletal muscle wasting in vitro and reflects sarcopenia in patients.
Ubachs J, van de Worp WRPH, Vaes RDW, Pasmans K, Langen RC, Meex RCR, van Bijnen AAJHM, Lambrechts S, Van Gorp T, Kruitwagen RFPM, Olde Damink SWM, Rensen SS. Ubachs J, et al. Among authors: lambrechts s. J Cachexia Sarcopenia Muscle. 2022 Feb;13(1):311-324. doi: 10.1002/jcsm.12885. Epub 2021 Dec 23. J Cachexia Sarcopenia Muscle. 2022. PMID: 34951138 Free PMC article.
117 results